Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients Suffering From Chronic Obstructive Pulmonary Disease II

This study has been completed.
Information provided by:
Boehringer Ingelheim Identifier:
First received: December 29, 2009
Last updated: May 4, 2011
Last verified: May 2011

The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Olodaterol (BI1744) Low
Drug: Olodaterol (BI1744) High
Drug: Tiotropium 18 mcg
Drug: Placebo (for Olodatero (BI1744)l)
Drug: Placebo (for Tiotropium)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour Forced Expiratory Volume After 1 Second (FEV1)-ti me Profiles of BI 1744 CL 5µg and 10µg (Oral Inhalation, Delivered by the Respimat® Inhaler) and Tiotropium Bromide 18µg (Oral Inhalation, Delivered by the HandiHaler®) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The primary objective will be to evaluate whether once daily treatment with low or high dose Olodaterol (BI 1744) administered via Respimat device is superior to once daily treatment with Placebo using FEV1 AUC12-24 responses after 6 weeks of treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • The co-primary efficacy endpoints are FEV1 AUC 0-12 response and FEV1 AUC12-24 response after 6 weeks of treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The key secondary objective will be to compare once daily treatment with low or high dose Odolaterol ( BI 1744) administered via the Respimat device to once daily treatment with tiotropium bromide (18mcg handihaler) using FEV1 AUC values. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • FEV1 AUC0-24 response after 6 weeks treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • FVC AUC0-12, FVC AUC12-24 and FVC AUC0-24 responses after 6 weeks treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Trough FEV1 and FVC responses after 6 weeks treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • FEV1 AUC0-3 and FVC AUC0-3 responses after 1st dose and after 6 weeks treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Peak FEV1 and FVC responses after 1st dose and after 6 weeks treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Individual FEV1 and FVC measurements at each time point after 1st dose (up to 3 hrs) and after 6 weeks (over 24 hrs) of treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Adverse events; vital signs: pulse rate and blood pressure (seated); Routine blood chemistry, haematology and urinalysis and 12-lead ECG [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 122
Study Start Date: January 2010
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Olodaterol (BI1744) Low
Low dose inhaled orally once daily from Respimat inhaler
Drug: Olodaterol (BI1744) Low
Low dose inhaled orally once daily from Respimat inhaler
Experimental: Olodaterol (BI1744) High
High dose inhaled orally once daily from Respimat inhaler
Drug: Olodaterol (BI1744) High
High dose inhaled orally once daily from Respimat inhaler
Active Comparator: Tiotropium 18 mcg
18 mcg inhaled once daily from HandiHaler
Drug: Tiotropium 18 mcg
18 mcg inhaled once daily from HandiHaler
Placebo Comparator: Placebo
Olodaterol placebo and/or Tiotropium placebo inhaled once daily
Drug: Placebo (for Olodatero (BI1744)l)
Placebo (olodaterol low and high dose) delivered by Respimat
Drug: Placebo (for Tiotropium)
Placebo (Tiotropium 18 mcg) delivered by HandiHaler


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Patients willing to participate with confirmed diagnosis of COPD
  • 40 years of age or older
  • having a 10 pack year smoking history
  • able to perform serial pulmonary function tests
  • able to use both a Dry powder inhaler (DPI) and Respimat device

Exclusion criteria:

  • Significant other disease
  • clinically relevant abnormal hematology, chemistry, or urinalysis
  • history of asthma
  • diagnosis of thyrotoxicosis
  • paroxysmal tachycardia related to beta agonists
  • history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year
  • active tuberculosis, cystic fibrosis, clinically evident bronchiectasis
  • significant alcohol or drug abuse
  • pulmonary resection
  • taking oral beta adrenergics
  • taking unstable oral steroids
  • daytime oxygen
  • enrolled in rehabilitation program
  • enrolled in another study or taking investigational products
  • pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control
  • those who are not willing to comply with pulmonary medication washouts
  Contacts and Locations
Please refer to this study by its identifier: NCT01040728

United States, Alabama
1222.40.11003 Boehringer Ingelheim Investigational Site
Jasper, Alabama, United States
United States, Florida
1222.40.11001 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1222.40.11002 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1222.40.49401 Boehringer Ingelheim Investigational Site
Berlin, Germany
1222.40.49403 Boehringer Ingelheim Investigational Site
Berlin, Germany
1222.40.49402 Boehringer Ingelheim Investigational Site
Hannover, Germany
1222.40.31003 Boehringer Ingelheim Investigational Site
Breda, Netherlands
1222.40.31002 Boehringer Ingelheim Investigational Site
Eindhoven, Netherlands
1222.40.31001 Boehringer Ingelheim Investigational Site
Heerlen, Netherlands
1222.40.47003 Boehringer Ingelheim Investigational Site
Arendal, Norway
1222.40.47002 Boehringer Ingelheim Investigational Site
Drammen, Norway
1222.40.47001 Boehringer Ingelheim Investigational Site
Trondheim, Norway
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT01040728     History of Changes
Other Study ID Numbers: 1222.40, 2009-014418-86
Study First Received: December 29, 2009
Last Updated: May 4, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Netherlands: Central Committee Research Involving Human Subjects
Norway: Norwegian Medicines Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Bronchodilator Agents
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses processed this record on April 15, 2014